Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare systems.
| Publicado en: | International Journal of Clinical Pharmacy Vol. 48; no. 4; pp. 1533 - 1548 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195342501&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195342501 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 22107703 BGX3 jtl: International Journal of Clinical Pharmacy issn: 22107703 maglogo: N pubinfo: dt: Aug2026 vid: 48 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 195342501 193004200 10.1007/s11096-026-02133-z 195342501 ppf: 1533 ppct: 15 formats: tig: atl: Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare systems. aug: au: Yang, Junhao Ding, Haixia affil: https://ror.org/059gcgy73 Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Jiangsu, People's Republic of China sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|